Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

A gold miner's shares surged 5%, driven by strong gains in its NYSE shares and a bullish note from UBS, which highlighted the company's stock as a top choice for ASX gold exposure amid rising gold ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Community driven content discussing all aspects of software development from DevOps to design patterns. When you install Java, the JDK comes with a number of helpful utilities packed within the ...

PYC Therapeutics Ltd’s latest earnings call for the second quarter of 2025 highlighted the company’s strategic focus on pipeline development and potential asset monetization. Despite no specific ...

PYC Therapeutics (ASX: PYC) presented its Q2 2025 investor webinar on May 30, outlining progress across its genetic medicine pipeline while facing continued market skepticism. The company’s stock ...

The secondary aim of the trial is to assess the drug’s efficacy when the trial extends to polycystic kidney disease patients in the second half of this year. Credit: SewCreamStudio / Shutterstock. · ...

The secondary aim of the trial is to assess the drug’s efficacy when the trial extends to polycystic kidney disease patients in the second half of this year. Credit: SewCreamStudio / Shutterstock. PYC ...

Barrenjoey’s research department initiated on PYC Therapeutics last month in hopes of strengthening its relationship with the budding biotech. But the inhabitants of the Vertical Village only had to ...

The last three months have been tough on PYC Therapeutics Limited (ASX:PYC) shareholders, who have seen the share price decline a rather worrying 36%. But that doesn't change the fact that the returns ...